CONTACT: COMPANY CONTACT: Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications Raptor Pharmaceutical Corp. (415) 408-6351 INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 firstname.lastname@example.org MEDIA CONTACT: Cammy Duong Canale Communications (619) 849-5382 email@example.com
NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5, 2015, after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update. Dial-in Information U.S. Dial-in Number: (877) 710-6201 International Dial-in Number: (616) 548-5611 Conference ID: 72182025 Replay U.S. Dial-in Number: (855) 859-2056 Replay International Dial-in Number: (404) 537-3406 Conference ID: 72182025 The dial-in replay will be available for seven days following the call. An audio webcast will be available online in the investor relations section of the company website at www.raptorpharma.com, with a webcast replay accessible for 90 days after the call. About Raptor Pharmaceutical Corp. Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases. With the acquisition of QUINSAIR TM, the company plans to develop MP-376, the pharmaceutical product known commercially as QUINSAIR, in cystic fibrosis (CF) and at least one of bronchiectasis (BE) or nontuberculous mycobacteria (NTM). In addition, Raptor is developing RP103, the pharmaceutical product known commercially as PROCYSBI ®, in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD) and mitochondrial diseases including Leigh syndrome. Raptor holds several orphan drug designations, including orphan drug exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. For additional information, please visit www.raptorpharma.com.